Rusfertide: First Self-Injected Drug to Cut Phlebotomy
Rusfertide, an investigational, first-in-class, self-injected peptide targeting the hepcidin pathway, shows efficacy in significantly reducing the need for phlebotomy in patients with polycythemia vera (PV) while improving quality-of-life symptoms, potentially representing an important new standard of care for the commonly undertreated condition.
'Rusfertide is the first agent to prospectively demonstrate a statistically significant improvement in the PROMIS Fatigue SF-8a and MFSAF patient-reported outcomes in patients with PV,' said lead investigator Andrew Tucker Kuykendall, MD, of the Moffitt Cancer Center, in Tampa, Florida, in presenting the findings at American Society of Clinical Oncology (ASCO) 2025 annual meeting.
'Rusfertide had a safety and tolerability profile consistent with rusfertide in prior studies.'
In PV, characterized by the overproduction of red blood cells, patients have an increased risk for thromboembolic events, along with symptoms ranging from pruritus, night sweats, difficulty concentrating and fatigue.
Patients with PV, characterized by an overproduction of blood cells in bone marrow, are at an increased risk for cardiovascular and thrombotic events, while also experiencing symptoms including potentially severe fatigue.
The traditional standard treatment includes phlebotomy to reduce excess red blood cells, and patients also often receive cytoreductive agents, mainly hydroxyurea, but also including interferon alfa-2b, ruxolitinib, and busulfan.
Despite those efforts, the treatment is often not sufficient in achieving or maintaining hematocrit control of < 45%, which is recommended to reduce the risk for a thromboembolic event.
Furthermore, phlebotomy is not just burdensome in requiring reliance of the health system, but the treatment can exacerbate iron deficiency, posing further quality of life issues.
If achieved, however, maintaining hematocrit control is associated with as much as a fourfold decreased risk for major events, Kuykendall explained.
Rusfertide, a hepcidin-mimetic compound, is meanwhile designed to mimic endogenous hepcidin, key in regulating levels of iron in the body.
With the drug showing favorable hematocrit control in the phase 2 REVIVE study, Kuykendall conducted the phase 3, double-blind VERIFY trial, enrolling 293 patients who required frequent phlebotomy, with or without stable cytoreductive therapy to control hematocrit.
The patients were randomized to treatment either with once-weekly rusfertide (n = 147) or placebo (n = 146) for the first 32 weeks of the study. All who completed that phase were eligible to join the open-label rusfertide phase from weeks 32 to 52.
About half of the patients in the study were treated with cytoreductive therapies to prevent thrombotic events.
In weeks 0 through 32, 56.5% of patients in the rusfertide group and 55.5% in the placebo group received concurrent cytoreductive therapy.
During the period from weeks 20 to 32, as many as 76.9% of patients receiving rusfertide achieved a clinical response compared with 32.9% of those who had received placebo ( P < .0001).
During weeks 0-32, those receiving rusfertide had a mean number of 0.5 phlebotomies vs 1.8 with placebo ( P < .0001).
As many as 72.8% of patients in the rusfertide group required no phlebotomies during the first 32 weeks compared with only 21.9% in the placebo group. Of note, the responses were consistent across subgroups, including based on level of risk or the type of concurrent cytoreductive therapy.
'Rusfertide reduced the mean number of phlebotomies vs placebo in weeks 0 through 32 by a statistically significant margin across subgroups, including PV risk category, geographic region and the use of concurrent cytoreductive therapy,' Kuykendall said.
For the key secondary endpoint, 62.6% of patients in the rusfertide group were able to successfully maintain hematocrit below 45% from weeks 0 to 32 compared with just 14.4% of those in the placebo group ( P < .0001).
Patients treated with rusfertide also demonstrated statistically significant improvement in measures of fatigue and other symptoms, as assessed on the PROMIS Fatigue SF-8a total T-score and MFSAF Total Symptom Score ( P < .03).
The most common treatment-emergent adverse events (AEs) in the rusfertide and placebo groups, respectively, were injection site reactions (55.9% and 32.9%), anemia (15.9% and 4.1%), and fatigue (15.2% and 15.8%).
Serious AEs occurred in 3.4% of those on rusfertide and 4.8% of patients on placebo; however, none were considered related to rusfertide treatment.
Importantly, cancer events were reported in just 1 patient on rusfertide and 7 patients on placebo.
Kuykendall noted that ongoing research will evaluate longer-term outcomes.
'Given this chronic malignancy, we are very focused on more long-term treatment outcomes such as transformation, safety as well as thrombosis, and ultimately we'll have to follow patients in this ongoing study during [subsequent phases] to see how these play out,' he said.
'Rusfertide demonstrated a manageable safety profile; it was consistent with prior studies, and based on this data we believe it represents a potential new treatment option for polycythemia vera,' Kuykendall added, noting that 'these data will ultimately be used to file marketing authorizations throughout the world.'
Reduction of Phlebotomy 'Highly Important' to Patients
Commenting on the study at the meeting, discussant Katherine Walsh, MD, an associate professor of medicine in the Division of Hematology and Oncology, Vanderbilt University Medical Center, in Nashville, Tennessee, called the results 'practice changing,' agreeing that 'rusfertide should become a standard of care for us for our patients in the near future.'
'The ability to reduce the need for phlebotomy, which can carry a heavy burden, causing severe fatigue, visual disturbances and iron deficiency, is a highly important goal for patients with PV,' she explained.
'These patients live with a high risk of thrombosis over time and that has significant impact on their survival, impact on quality of life, and can be fatal in and of itself from those thrombotic events.'
In discussing further potential benefits, Kuykendall noted that rusfertide is of interest to patients who may not be responding well to cytoreductive therapy.
'I think our cytoreductive therapy options are limited in what they can offer to patients,' he noted in discussion of the study.
'They certainly reduce thrombotic events, they can control some blood counts, but they do have long term side-effect profile issues, tolerability issues and they don't do as much as I would like for patients on in terms of quality of life,' he added.
'So I think this is where we can add to our current cytoreductive therapies that brings something else to the table.'
Walsh agreed, noting that 'I have a number of patients who are referred because they don't want to go on a cytoreductive agent if they can avoid it, and I think having this option with this different mechanism of action will be appealing to [those] patients wanting to avoid cytoreduction.'
Adding to the Chorus of Support for New Standard of Care
Further commenting on the study in an ASCO Daily News report, Julie Gralow, MD, ASCO's chief medical officer, noted the importance of the cancer results.
'We know that acute myeloid leukemia (AML) and other malignancies can occur in patients with polycythemia,' she explained. 'AML occurs in about 3% of these patients over 10 years.'
'With just one cancer in the rusfertide group, and seven in the placebo arm, [AML] clearly did not increase and may, although not significantly, have decreased.'
Considering the reductions in the need for phlebotomy and other benefits, Gralow agreed that 'this really should become a new standard of care for patients who are requiring phlebotomy that have polycythemia.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 days ago
- Medscape
ASCO 2025: New Standards Reshape Care in mBC
Heather McArthur, MD, describes how the 2025 ASCO Annual Meeting brought exciting advances in the metastatic breast cancer space. In PD-L1-positive triple-negative breast cancer, sacituzumab govitecan combined with pembrolizumab significantly improved progression-free survival over standard chemotherapy plus pembrolizumab, quickly becoming a new standard of care. Similarly, in HER2-positive disease, trastuzumab deruxtecan combined with pertuzumab outperformed traditional THP therapy, offering a new frontline option. Overall, these findings signify a major shift in how to treat metastatic breast cancer.
Yahoo
2 days ago
- Yahoo
Transgene completes initial screening in Phase II part of TG4050 vaccine trial
Transgene has completed the initial subject screening for the Phase II segment of its Phase I/II trial of individualised neoantigen therapeutic vaccine, TG4050, as a monotherapy in the adjuvant treatment of human papillomavirus (HPV)-negative squamous head and neck cancers. The vaccine is based on the myvac platform powered by its partner NEC's AI to enhance antigen selection. During the Phase I portion of the trial, all subjects treated with the vaccine remained disease-free post a minimum follow-up of two years, demonstrating clinical proof of principle. Translational data indicated that these subjects showed sustained T cell responses at 24 months. Meeting all trial endpoints, the findings were shared at the American Society of Clinical Oncology (ASCO 2025) annual meeting. The company anticipates completing the randomisation of all subjects in the Phase II part by the end of this year, after a second screening carried out post-surgery and adjuvant radiotherapy. Around 80 subjects who have completely responded to adjuvant therapy are expected to be enrolled and randomised in the Phase I/II trial. The first immunogenicity data from the Phase II part are projected to be available in the second half of 2026, with preliminary efficacy data anticipated in the second half of 2027. The trial is assessing the treatment benefits of the vaccine in individuals at risk of relapse. So far, 32 evaluable patients have been included in the Phase I part, with the Phase II continuing globally. Transgene chief medical officer Dr Emmanuelle Dochy said: 'Timely completion of first patient screening of the Phase II part of our Phase I/II trial is an important milestone for Transgene and brings us one step closer to providing a new treatment option for patients living with operable squamous head and neck cancer. 'With meaningful data readouts expected over the next two years, we are preparing to deliver important data for TG4050 and, at the same time, explore its wider potential. We are grateful to the patients, their families, investigators, and clinical staff whose commitment made this achievement possible.' "Transgene completes initial screening in Phase II part of TG4050 vaccine trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Medscape
2 days ago
- Medscape
Sexual Effects Persist After Cervical Cancer Treatment
CHICAGO — Patients treated for cervical cancer need dedicated survivorship care to address long-term symptoms and sexual health concerns. That was the conclusion of a review of patient-reported outcomes (PROs) from among 919 women in the international phase 3 OUTBACK trial. The PROs showed that numerous sexual health symptoms and concerns persist 3 years following treatment, Linda Mileshkin, MD, reported at the American Society of Clinical Oncology (ASCO) 2025. The 10 top-ranked PROs at 1-year follow-up — based on responses from the 64% of trial participants who completed a European Organisation for Research and Treatment of Cancer (EORTC) questionnaire — and their persistence or resolution at 2-3 years, based on responses from 37% of trial participants, are listed in the table below. Table. Frequency and Duration of Top-Ranked Moderate-to-Severe Symptoms 10 most common moderate-to-severe PROs after cervical cancer treatment Number (percentage) of patients reporting symptoms at 1 year Number (percentage) of patients reporting symptoms at year 2 or 3 Worries about future health 135 (44) 49 (36) Hot flashes/sweats 132 (37) 49 (37) Frequent urination 126 (35) 45 (36) Sexual activity not enjoyable 125 (64) 43 (34) Trouble sleeping 117 (32) 37 (32) Feeling tired 104 (29) 33 (32) Changes in bowel habits 102 (28) 41 (40) Financial difficulties 101 (28) 32 (32) Pain 96 (27) 23 (24) Dissatisfied with body 95 (26) 27 (28) PROs = patient-reported outcomes PROs were based on responses to the EORTC core questionnaire QLQ-C30; cervical cancer module QLQ-CX24 (questions 50-54 only for sexually active points); EORTC Item Library questions on abdominal, urinary, bowel, and chemotherapy side effects; and FACT-GOG-NTX-4 neurotoxicity over 36 months. A moderate-to-severe long-term symptom issue was defined as a score in the worst 2 response categories (EORTC items), a total score ≤ 8/16 on FACT-GOG-NTX4 at years 1, 2, or 3 for Objectives 1-2, or an equivalent subscale score for Objective 3. Adapted from Mileshkin L. Program and abstracts of the 2025 ASCO Annual Meeting; May 30 to June 3, 2025; Chicago, Illinois. Abstract 5503. The OUTBACK trial assessed the addition of adjuvant chemotherapy (ACT) after chemoradiotherapy (CRT) for the treatment of locally advanced cervical cancer. That study demonstrated that ACT increased adverse events without improving overall survival compared with CRT alone. Regardless of whether patients were assigned to the CRT + ACT or CRT-only treatment group, the issues and frequencies from PROs in the current analysis were observed, reported Mileshkin, who is director of Medical Oncology at the Peter MacCallum Cancer Centre in Melbourne, Australia, and first author for the OUTBACK trial. Given the low questionnaire completion rates at 2-3 years, the PROs may represent underestimates, she said. At 1 year, moderate-to-severe peripheral neuropathy affected 24% and 18% of those who received CRT + ACT and those who received only CRT, respectively, and at 3 years, the corresponding rates were 19% and 12%. At baseline, 77% of patients reported no sexual activity in the prior 4 weeks, and at years 1, 2, or 3, 92% reported low sexual activity, 68% reported low enjoyment, 40% reported moderate-to-severe vaginal tightness, 37% reported vaginal dryness during sex, and 32% were moderately to severely worried that sex would be painful. The rates of poor sexual enjoyment were somewhat lower with CRT-only treatment, whereas the rates of sexual worry were higher among those with CRT + ACT. Age younger than 60 years was an independent risk factor for experiencing sexual concerns. Though limited by the low completion rate at 3 years and a lack of data on menopausal symptom management and use of vaginal estrogen or dilators, the findings underscored the importance of discussing and managing the long-term effects of CRT with patients, Mileshkin said during her presentation at the meeting. Cervical cancer treatment in clinical practice will change over time, but 'meanwhile, there's going to be hundreds of thousands of women who've had this type of treatment who continue to recover and live with these side effects,' she stressed. 'I hope [these findings] will help clinicians remember to ask patients about these issues and try to address them because women won't necessarily volunteer them themselves.' Mileshkin disclosed honoraria from GlaxoSmithKline and the limbic; research funding from BeiGene; and travel, accommodations, expenses, and another relationship with Roche.
